VECT 16.85 (+0%)
CH1109007893BiotechnologyBiotechnology

VectivBio Holding (VECT) Stock Highlights

16.85 | +0%
2023-08-10 14:04:37
VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. The product candidate is apraglutide, which is a next generation, long-acting synthetic peptide analog of glucagon-like peptide-2, or GLP-2, which is developed as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome.

Statistics

Range Today
16.85 16.85
Volume Today 0
Range 1 Year
4.25 16.98
Volume 1 Year 70.96M
Range 3 Year
2.74 37.7
Volume 3 Year 87.67M
Range 10 Year
2.74 37.7
Volume 10 Year 87.67M

Highlights

Market Capitalization 1.06B (small)
Floating Shares 31.09M
Current Price 16.85
Price To Earnings -8
Price To Revenue 30.95
Price To Book 4.95
Earnings Per Share -2.1
Payout Ratio 0%

Performance

Latest 0%
1 Month -0.3%
3 Months +89.11%
6 Months +105.49%
1 Year +184.15%
3 Years -0.88%
5 Years -0.88%
10 Years -0.88%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.